Literature DB >> 15260917

Pharmacokinetic interactions of drugs with St John's wort.

Shufeng Zhou1, Eli Chan, Shen-Quan Pan, Min Huang, Edmund J D Lee.   

Abstract

There is a worldwide increasing use of herbs which are often administered in combination with therapeutic drugs, raising the potential for herb-drug interactions. St John's wort (Hypericum perforatum) is one of the most commonly used herbal antidepressants. A literature search was performed using Medline (via Pubmed), Biological Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their inception to September 2003) to identify known drug interaction with St John's wort. The available data indicate that St John's wort is a potent inducer of CYP 3A4 and P-glycoprotein (PgP), although it may inhibit or induce other CYPs, depending on the dose, route and duration of administration. Data from human studies and case reports indicate that St John's wort decreased the blood concentrations of amitriptyline, cyclosporine, digoxin, fexofenadine, indinavir, methadone, midazolam, nevirapine, phenprocoumon, simvastatin, tacrolimus, theophylline and warfarin, whereas it did not alter the pharmacokinetics of carbamazepine, dextromethorphan, mycophenolic acid and pravastatin. St John's wort decreased the plasma concentration of the active metabolite SN-38 in cancer patients receiving irinotecan treatment. St John's wort did not alter the pharmacokinetics of tolbutamide, but increased the incidence of hypoglycaemia. Several cases have been reported that St John's wort decreased cyclosporine blood concentration leading to organ rejection. St John's wort caused breakthrough bleeding and unplanned pregnancies when used concomitantly with oral contraceptives. It also caused serotonin syndrome when coadministered with selective serotonin-reuptake inhibitors (e.g. sertaline and paroxetine). Both pharmacokinetic and pharmacodynamic components may play a role in these interactions. Because the potential interaction of St John's wort with other drugs is a major safety concern, additional systematic research on herb-drug interactions and appropriate regulation in herbal safety and efficacy is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15260917     DOI: 10.1177/0269881104042632

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  38 in total

1.  Highly variable contents of phenolics in St. John's Wort products affect their transport in the human intestinal Caco-2 cell model: pharmaceutical and biopharmaceutical rationale for product standardization.

Authors:  Song Gao; Wen Jiang; Taijun Yin; Ming Hu
Journal:  J Agric Food Chem       Date:  2010-06-09       Impact factor: 5.279

2.  Use of complementary and alternative medicine in a large sample of anxiety patients.

Authors:  Alexander Bystritsky; Sarit Hovav; Cathy Sherbourne; Murray B Stein; Raphael D Rose; Laura Campbell-Sills; Daniela Golinelli; Greer Sullivan; Michelle G Craske; Peter P Roy-Byrne
Journal:  Psychosomatics       Date:  2012-02-01       Impact factor: 2.386

Review 3.  Clinical risk management of herb-drug interactions.

Authors:  Peter A G M De Smet
Journal:  Br J Clin Pharmacol       Date:  2006-11-20       Impact factor: 4.335

4.  Inhibitory effect of the herbal antidepressant St. John's wort (Hypericum perforatum) on rat gastric motility.

Authors:  Raffaele Capasso; Francesca Borrelli; Gabriella Aviello; Francesco Capasso; Angelo A Izzo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

5.  Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.

Authors:  Brandon Swift; Xianbin Tian; Kim L R Brouwer
Journal:  Pharm Res       Date:  2009-06-04       Impact factor: 4.200

Review 6.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

7.  The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Bernhard Uehleke; Sebastian Klammt; Ralf G Mundkowski; Wolfram Miekisch; Hartwig Sievers; Steffen Bauer; Bruno Frank; Guenther Kundt; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2005-12-10       Impact factor: 2.953

8.  The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.

Authors:  Lan Fan; Gan Zhou; Dong Guo; Ya-Li Liu; Wang-Qing Chen; Zhao-Qian Liu; Zhi-Rong Tan; Deng Sheng; Hong-Hao Zhou; Wei Zhang
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

9.  Substitutes or complements? Diagnosis and treatment with non-conventional and conventional medicine.

Authors:  Aida Isabel Tavares
Journal:  Int J Health Policy Manag       Date:  2015-03-03

10.  St. John's Wort Attenuates Colorectal Carcinogenesis in Mice through Suppression of Inflammatory Signaling.

Authors:  Soumen K Manna; Srujana Golla; Jaya Prakash Golla; Naoki Tanaka; Yan Cai; Shogo Takahashi; Kristopher W Krausz; Tsutomu Matsubara; Ilia Korboukh; Frank J Gonzalez
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.